On February 5, Teva Pharmaceutical announced the enrollment of the first patient in the MODERATO study, a phase 4 clinical study designed to evaluate the effect of Azilect (rasagiline tablets) on cognitive function in adults with Parkinson’s disease who also have mild cognitive impairment (PD-MCI). ...[Read More]

On April 3, UCB announced the approval by the Food and Drug Administration (FDA) of Neupro (rotigotine transdermal system) for treatment of the signs and symptoms of advanced-stage idiopathic Parkinson’s disease (PD) and as a treatment for moderate-to-severe primary restless legs syndrome (RLS). Neupro was previously approved for early-stage idiopathic PD. ...[Read More]

Abstract Teaser ...[Read More]